Allergic Asthma

Respiratory
6
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
3 programs
3
ANTI-IGE THERAPYPhase 4
OmalizumabPhase 4Monoclonal Antibody1 trial
OmalizumabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT00208234Unknown22Est. Sep 2011
NCT01125748Completed176Est. Aug 2013
Novartis
NovartisBASEL, Switzerland
1 program
1
ANTI-IGE THERAPYPhase 41 trial
Active Trials
NCT00283504Completed13Est. Jan 2009
HELP Therapeutics
HELP TherapeuticsChina - Nanjing
1 program
1
Inhaled corticosteroidPhase 41 trial
Active Trials
NCT00980707Completed10Est. Nov 2010
Jasper Therapeutics
Jasper TherapeuticsREDWOOD CITY, CA
1 program
1
BriquilimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT06592768TerminatedEst. Aug 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GenentechOmalizumab
HELP TherapeuticsInhaled corticosteroid
NovartisANTI-IGE THERAPY
GenentechOmalizumab
Jasper TherapeuticsBriquilimab

Clinical Trials (5)

Total enrollment: 221 patients across 5 trials

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

Start: May 2010Est. completion: Aug 2013176 patients
Phase 4Completed
NCT00980707HELP TherapeuticsInhaled corticosteroid

Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma

Start: Aug 2009Est. completion: Nov 201010 patients
Phase 4Completed
NCT00283504NovartisANTI-IGE THERAPY

A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy

Start: Jan 2006Est. completion: Jan 200913 patients
Phase 4Completed

Effect of Xolair on Airway Hyperresponsiveness

Start: Jan 2004Est. completion: Sep 201122 patients
Phase 4Unknown

A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

Start: Nov 2024Est. completion: Aug 2025
Phase 1Terminated

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

Monoclonal Antibody is the dominant modality (100% of programs)
4 companies competing in this space